問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation

Division of Neurology

更新時間:2023-09-19

陳與潔
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

2Cases

2023-03-01 - 2025-09-09

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
  • Condition/Disease

    Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

  • Test Drug

    Rozanolixizumab

Participate Sites
6Sites

Not yet recruiting6Sites

2025-01-01 - 2030-12-31

Phase III

Active
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phase
  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    Remibrutinib

Participate Sites
5Sites

Recruiting5Sites